Back to results
US 7,598,353 B2Granted
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AssigneeAlexion Pharmaceuticals, Inc.
InventorsKatherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
Life of this patent
Estimating the term…
Abstract
Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
Claims13
A fusion molecule comprising:
- a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen binding fragment thereof that binds to CD200 comprising:
- (i) a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO:
- 209, (ii) a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO:
- 209, (iii) a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO:
- 209, (iv) a heavy chain CDR1 having the sequence set forth in SEQ ID NO:
- 149, (v) a heavy chain CDR2 having the sequence set forth in SEQ ID NO:
- 174, and (vi) a heavy chain CDR3 having the sequence set forth in SEQ ID NO:
- 195;
- and a second portion that is a toxin.
6 more elements
Dependencies are inferred from the claim text.